AstraZeneca Pharma India shares extended the losing streak on fifth consecutive session on April 7 despite company received permission to import for sale and distribution of Osimertinib Tablets.
At 09:46 hrs AstraZeneca Pharma was quoting at Rs 7,590.70, down Rs 317.80, or 4.02 percent.
"...... has received permission from the Central Drugs Standard Control Organization (CDSCO), Directorate General of Health Services, Government of India to import for sale and distribution of Osimertinib Tablets 40 mg & 80 mg (TAGRISSO) for an additional indication,' company said in its release.
Through this approval, Osimertinib is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, it added.
This permission paves way for the marketing of Osimertinib Tablets in India for the specified additional indication, subject to the receipt of related statutory approvals, if any.
Catch all the market action on our live blog
The company has discontinued the manufacturing and marketing of the product Prolonged release Isosorbide-5-mononitrate Tablets BP 30 mg and 60 mg (Imdur) from April 1, 2025.
Last month company received CDSCO permission to import for sale and distribution of Durvalumab solution for infusion 120 mg/2.4 ml and 500 mg/10 ml (Imfinzi) for an additional indication.
The share touched a 52-week high of Rs 9,049.95 and a 52-week low of Rs 5,000.00 on 24 March, 2025 and 08 May, 2024, respectively.
Currently, the stock is trading 16.22 percent below its 52-week high and 51.64 percent above its 52-week low.
Market capitalisation stands at Rs 18,955.00 crore.
The share price rose 49 percent in the last one-year.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
